Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Астенический синдром в неврологической и общетерапевтической практике
Астенический синдром в неврологической и общетерапевтической практике
Шишкова В.Н. Астенический синдром в неврологической и общетерапевтической практике. Consilium Medicum. 2020; 22 (9): 65–67.
DOI: 10.26442/20751753.2020.9.200343
DOI: 10.26442/20751753.2020.9.200343
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассматриваются основные проявления астенических расстройств у коморбидных пациентов в практике врачей первичного звена. Обсуждаются патогенез данных проявлений и возможность подбора оптимальной терапии. Рассматривается спектр терапевтического влияния препарата Церебролизин применительно к данной категории пациентов.
Ключевые слова: постинфекционная астения, органическая астения, Церебролизин.
Key words: post-infectious asthenia, organic asthenia, Cerebrolysin.
Ключевые слова: постинфекционная астения, органическая астения, Церебролизин.
________________________________________________
Key words: post-infectious asthenia, organic asthenia, Cerebrolysin.
Полный текст
Список литературы
1. Смулевич А.Б. Астения в общесоматической и психиатрической сети. Психические расстройства в общей медицине. 2010; 1.
[Smulevich A.B. Asteniia v obshchesomaticheskoi i psikhiatricheskoi seti. Mental Disorders in General Medicine. 2010; 1 (in Russian).]
2. Порошина Е.Г., Немировский В.С. Астения, неврастения, синдром хронической усталости: сходство и различия. Учебно-методическое пособие. Под ред. проф. В.И.Симаненкова. СПб.: АСТ345, 2012.
[Poroshina E.G., Nemirovsky V.S. Asthenia, neurasthenia, chronic fatigue syndrome: similarities and differences. Study guide. Ed. prof. V.I.Simanenkova. Saint Petersburg: AST345, 2012 (in Russian).]
3. Психические расстройства и расстройства поведения (F00–F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общ. ред. Б.А.Казаковцева, В.Б.Голланда. М., 1998.
[Psikhicheskie rasstroistva i rasstroistva povedeniia (F00–F99). Klass V MKB-10, adaptirovannyi dlia ispol'zovaniia v Rossiiskoi Federatsii. Red. B.A.Kazakovtseva, V.B.Gollanda. Moscow, 1998 (in Russian).]
4. Повереннова И.Е., Золотовская И.А., Безгиназ Е.В. Диагностика и лечение астенического синдрома у лиц пожилого возраста, перенесших ОРВИ. Журн. неврологии и психиатрии 2014; 9: 73–6.
[Poverennova I.E., Zolotovskaia I.A., Bezginaz E.V. Diagnostika i lechenie astenicheskogo sindroma u lits pozhilogo vozrasta, perenesshikh ORVI. Zhurn. nevrologii i psikhiatrii 2014; 9: 73–6 (in Russian).]
5. Шишкова В.Н. Нейропротекция у пациентов с артериальной гипертонией: минимизация неблагоприятного прогноза. Терапевтический архив. 2014; 86 (8): 113–8.
[Shishkova V.N. Neuroprotection in patients with arterial hypertension: minimizing a poor prognosis. Therapeutic Archive. 2014; 86 (8): 113–8 (in Russian).]
6. Шишкова В.Н. Когнитивные нарушения как универсальный клинический синдром в практике терапевта. Терапевтический архив. 2014; 86 (11): 128–34.
[Shishkova V.N. Cognitive impairment as a universal clinical syndrome in the practice of a therapist. Therapeutic Archive. 2014; 86 (11): 128–34 (in Russian).]
7. Xiong TY, Redwood S, Prendergast B et al. Coronoviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020: ehaa23. DOI: 10.1093/eurheartj/ehaa231
8. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. DOI: 10.1001/jama.2020.1585
9. The world health report 2002 – Reducing Risks, Promoting Healthy Life. World Health Organization 2002; 186: 192.
10. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017; 11: 372–93.
11. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121 (4): 258–64.
12. Шишкова В.Н. Весенний сезон острых респираторных инфекций: что это означает для коморбидного пациенты и как к нему подготовиться. Лечебное дело. 2019; 4: 122–8.
[Shishkova V.N. Vesennii sezon ostrykh respiratornykh infektsii: chto eto oznachaet dlia komorbidnogo patsienty i kak k nemu podgotovit'sia. Lechebnoe delo. 2019; 4: 122–8 (in Russian).]
13. Болдырева А.А., Стволинский С.Л., Федорова Т.Н. Экспериментальные аспекты ишемии мозга и окислительного стресса. В кн.: Очерки ангионеврологии. Под ред. З.А.Суслиной. М.: Атмосфера, 2005; с. 41–9.
[Boldyreva A.A., Stvolinsky S.L., Fedorova T.N. Experimental aspects of cerebral ischemia and oxidative stress. In the book: Essays on angioneurology. Ed. Z.A.Suslina. Moscow: Atmosphere, 2005; p. 41–9 (in Russian).]
14. Шишкова В.Н. Особенности развития неврологических осложнений у пациентов с метаболическим синдромом: возможность коррекции и профилактики. Терапевтический архив. 2015; 87 (1): 109–14.
[Shishkova V.N. Features of the development of neurological complications in patients with metabolic syndrome: the possibility of correction and prevention. Therapeutic Archive. 2015; 87 (1): 109–14 (in Russian).]
15. Шишкова В.Н. На приеме – пожилой коморбидный пациент: расставляем акценты. Consilium Medicum. 2019; 21 (9): 48–53. DOI: 10.26442/20751753.2019.9.190500
[Shishkova V.N. An elderly comorbid patient: prioritizing. Consilium Medicum. 2019; 21 (9): 48–53. DOI: 10.26442/20751753.2019.9.190500 (in Russian).]
16. Громова О.А., Торшин И.Ю., Гоголева И.В. Механизмы нейротрофического и нейропротекторного действия препарата Церебролизин при ишемии артерий головного мозга. Журн. неврологии и психиатрии. 2014; 3 (2): 43–50.
[Gromova O.A., Torshin I.Iu., Gogoleva I.V. Mekhanizmy neirotroficheskogo i neiroprotektornogo deistviia preparata Tserebrolizin pri ishemii arterii golovnogo mozga. Zhurn. nevrologii i psikhiatrii. 2014; 3 (2): 43–50 (in Russian).]
17. Zhang Ch, Chopp M et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010; 88: 3275–81.
18. Ubhi K, Rockenstein E, Vazquez-Roque R et al. Cerebrolysin modulates nerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res 2013; 91: 167–77.
19. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012; 48 (Suppl. A): 3–24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716
20. Boado RJ. Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 1995; 197 (3): 179–82.
21. Boado RJ. Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 1996; 220: 53–6.
22. Boado RJ, Wu D, Pardridge WM, Windisch M. In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain. In: XVI World Congress of Neurology. Buenos Aires, 1997. Abstracts. N. 2–07–06.
23. Boado RJ. Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors. J Neural Transm 1998; 53 (Suppl.): 323–31.
24. Boado RJ. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides. Eur J Neurol 1999; 6 (Suppl. 3): 37.
25. Mooradian AD, Chung HC, Shan GN. GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 1997; 18: 469–74.
26. Windisch M, Piswanger A. In vitro effects of peptide derivates and extracts from calf blood on the oxidative metabolism of brain, liver and heart muscle homogenates of the rat. Drug Res 1985; 35: 87–9.
27. Чуканова Е.И. Сравнительный анализ эффективности Церебролизина при лечении пациентов с хронической ишемией мозга. Фармакоэкономические аспекты. Трудный пациент. 2011; 9 (1): 32–9.
[Chukanova E.I. Sravnitel'nyi analiz effektivnosti Tserebrolizina pri lechenii patsientov s khronicheskoi ishemiei mozga. Farmakoekonomicheskie aspekty. Trudnyi patsient. 2011; 9 (1): 32–9 (in Russian).]
28. Чутко Л.С., Сурушкина С.Ю., Рожкова А.В. и др. Астенические расстройства и когнитивные нарушения у пациентов с головной болью напряжения. Журн. неврологии и психиатрии/ 2013; 5: 25–9.
[Chutko L.S., Surushkina S.Iu., Rozhkova A.V. i dr. Astenicheskie rasstroistva i kognitivnye narusheniia u patsientov s golovnoi bol'iu napriazheniia. Zhurn. nevrologii i psikhiatrii/ 2013; 5: 25–9 (in Russian).]
2. Poroshina E.G., Nemirovsky V.S. Asthenia, neurasthenia, chronic fatigue syndrome: similarities and differences. Study guide. Ed. prof. V.I.Simanenkova. Saint Petersburg: AST345, 2012 (in Russian).
3. Psikhicheskie rasstroistva i rasstroistva povedeniia (F00–F99). Klass V MKB-10, adaptirovannyi dlia ispol'zovaniia v Rossiiskoi Federatsii. Red. B.A.Kazakovtseva, V.B.Gollanda. Moscow, 1998 (in Russian).
4. Poverennova I.E., Zolotovskaia I.A., Bezginaz E.V. Diagnostika i lechenie astenicheskogo sindroma u lits pozhilogo vozrasta, perenesshikh ORVI. Zhurn. nevrologii i psikhiatrii 2014; 9: 73–6 (in Russian).
5. Shishkova V.N. Neuroprotection in patients with arterial hypertension: minimizing a poor prognosis. Therapeutic Archive. 2014; 86 (8): 113–8 (in Russian).
6. Shishkova V.N. Cognitive impairment as a universal clinical syndrome in the practice of a therapist. Therapeutic Archive. 2014; 86 (11): 128–34 (in Russian).
7. Xiong TY, Redwood S, Prendergast B et al. Coronoviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020: ehaa23. DOI: 10.1093/eurheartj/ehaa231
8. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. DOI: 10.1001/jama.2020.1585
9. The world health report 2002 – Reducing Risks, Promoting Healthy Life. World Health Organization 2002; 186: 192.
10. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017; 11: 372–93.
11. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121 (4): 258–64.
12. Shishkova V.N. Vesennii sezon ostrykh respiratornykh infektsii: chto eto oznachaet dlia komorbidnogo patsienty i kak k nemu podgotovit'sia. Lechebnoe delo. 2019; 4: 122–8 (in Russian).
13. Boldyreva A.A., Stvolinsky S.L., Fedorova T.N. Experimental aspects of cerebral ischemia and oxidative stress. In the book: Essays on angioneurology. Ed. Z.A.Suslina. Moscow: Atmosphere, 2005; p. 41–9 (in Russian).
14. Shishkova V.N. Features of the development of neurological complications in patients with metabolic syndrome: the possibility of correction and prevention. Therapeutic Archive. 2015; 87 (1): 109–14 (in Russian).
15. Shishkova V.N. An elderly comorbid patient: prioritizing. Consilium Medicum. 2019; 21 (9): 48–53. DOI: 10.26442/20751753.2019.9.190500 (in Russian).
16. Gromova O.A., Torshin I.Iu., Gogoleva I.V. Mekhanizmy neirotroficheskogo i neiroprotektornogo deistviia preparata Tserebrolizin pri ishemii arterii golovnogo mozga. Zhurn. nevrologii i psikhiatrii. 2014; 3 (2): 43–50 (in Russian).
17. Zhang Ch, Chopp M et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010; 88: 3275–81.
18. Ubhi K, Rockenstein E, Vazquez-Roque R et al. Cerebrolysin modulates nerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res 2013; 91: 167–77.
19. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012; 48 (Suppl. A): 3–24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716
20. Boado RJ. Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 1995; 197 (3): 179–82.
21. Boado RJ. Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 1996; 220: 53–6.
22. Boado RJ, Wu D, Pardridge WM, Windisch M. In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain. In: XVI World Congress of Neurology. Buenos Aires, 1997. Abstracts. N. 2–07–06.
23. Boado RJ. Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors. J Neural Transm 1998; 53 (Suppl.): 323–31.
24. Boado RJ. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides. Eur J Neurol 1999; 6 (Suppl. 3): 37.
25. Mooradian AD, Chung HC, Shan GN. GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 1997; 18: 469–74.
26. Windisch M, Piswanger A. In vitro effects of peptide derivates and extracts from calf blood on the oxidative metabolism of brain, liver and heart muscle homogenates of the rat. Drug Res 1985; 35: 87–9.
27. Chukanova E.I. Sravnitel'nyi analiz effektivnosti Tserebrolizina pri lechenii patsientov s khronicheskoi ishemiei mozga. Farmakoekonomicheskie aspekty. Trudnyi patsient. 2011; 9 (1): 32–9 (in Russian).
28. Chutko L.S., Surushkina S.Iu., Rozhkova A.V. i dr. Astenicheskie rasstroistva i kognitivnye narusheniia u patsientov s golovnoi bol'iu napriazheniia. Zhurn. nevrologii i psikhiatrii/ 2013; 5: 25–9 (in Russian).
[Smulevich A.B. Asteniia v obshchesomaticheskoi i psikhiatricheskoi seti. Mental Disorders in General Medicine. 2010; 1 (in Russian).]
2. Порошина Е.Г., Немировский В.С. Астения, неврастения, синдром хронической усталости: сходство и различия. Учебно-методическое пособие. Под ред. проф. В.И.Симаненкова. СПб.: АСТ345, 2012.
[Poroshina E.G., Nemirovsky V.S. Asthenia, neurasthenia, chronic fatigue syndrome: similarities and differences. Study guide. Ed. prof. V.I.Simanenkova. Saint Petersburg: AST345, 2012 (in Russian).]
3. Психические расстройства и расстройства поведения (F00–F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общ. ред. Б.А.Казаковцева, В.Б.Голланда. М., 1998.
[Psikhicheskie rasstroistva i rasstroistva povedeniia (F00–F99). Klass V MKB-10, adaptirovannyi dlia ispol'zovaniia v Rossiiskoi Federatsii. Red. B.A.Kazakovtseva, V.B.Gollanda. Moscow, 1998 (in Russian).]
4. Повереннова И.Е., Золотовская И.А., Безгиназ Е.В. Диагностика и лечение астенического синдрома у лиц пожилого возраста, перенесших ОРВИ. Журн. неврологии и психиатрии 2014; 9: 73–6.
[Poverennova I.E., Zolotovskaia I.A., Bezginaz E.V. Diagnostika i lechenie astenicheskogo sindroma u lits pozhilogo vozrasta, perenesshikh ORVI. Zhurn. nevrologii i psikhiatrii 2014; 9: 73–6 (in Russian).]
5. Шишкова В.Н. Нейропротекция у пациентов с артериальной гипертонией: минимизация неблагоприятного прогноза. Терапевтический архив. 2014; 86 (8): 113–8.
[Shishkova V.N. Neuroprotection in patients with arterial hypertension: minimizing a poor prognosis. Therapeutic Archive. 2014; 86 (8): 113–8 (in Russian).]
6. Шишкова В.Н. Когнитивные нарушения как универсальный клинический синдром в практике терапевта. Терапевтический архив. 2014; 86 (11): 128–34.
[Shishkova V.N. Cognitive impairment as a universal clinical syndrome in the practice of a therapist. Therapeutic Archive. 2014; 86 (11): 128–34 (in Russian).]
7. Xiong TY, Redwood S, Prendergast B et al. Coronoviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020: ehaa23. DOI: 10.1093/eurheartj/ehaa231
8. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. DOI: 10.1001/jama.2020.1585
9. The world health report 2002 – Reducing Risks, Promoting Healthy Life. World Health Organization 2002; 186: 192.
10. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017; 11: 372–93.
11. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121 (4): 258–64.
12. Шишкова В.Н. Весенний сезон острых респираторных инфекций: что это означает для коморбидного пациенты и как к нему подготовиться. Лечебное дело. 2019; 4: 122–8.
[Shishkova V.N. Vesennii sezon ostrykh respiratornykh infektsii: chto eto oznachaet dlia komorbidnogo patsienty i kak k nemu podgotovit'sia. Lechebnoe delo. 2019; 4: 122–8 (in Russian).]
13. Болдырева А.А., Стволинский С.Л., Федорова Т.Н. Экспериментальные аспекты ишемии мозга и окислительного стресса. В кн.: Очерки ангионеврологии. Под ред. З.А.Суслиной. М.: Атмосфера, 2005; с. 41–9.
[Boldyreva A.A., Stvolinsky S.L., Fedorova T.N. Experimental aspects of cerebral ischemia and oxidative stress. In the book: Essays on angioneurology. Ed. Z.A.Suslina. Moscow: Atmosphere, 2005; p. 41–9 (in Russian).]
14. Шишкова В.Н. Особенности развития неврологических осложнений у пациентов с метаболическим синдромом: возможность коррекции и профилактики. Терапевтический архив. 2015; 87 (1): 109–14.
[Shishkova V.N. Features of the development of neurological complications in patients with metabolic syndrome: the possibility of correction and prevention. Therapeutic Archive. 2015; 87 (1): 109–14 (in Russian).]
15. Шишкова В.Н. На приеме – пожилой коморбидный пациент: расставляем акценты. Consilium Medicum. 2019; 21 (9): 48–53. DOI: 10.26442/20751753.2019.9.190500
[Shishkova V.N. An elderly comorbid patient: prioritizing. Consilium Medicum. 2019; 21 (9): 48–53. DOI: 10.26442/20751753.2019.9.190500 (in Russian).]
16. Громова О.А., Торшин И.Ю., Гоголева И.В. Механизмы нейротрофического и нейропротекторного действия препарата Церебролизин при ишемии артерий головного мозга. Журн. неврологии и психиатрии. 2014; 3 (2): 43–50.
[Gromova O.A., Torshin I.Iu., Gogoleva I.V. Mekhanizmy neirotroficheskogo i neiroprotektornogo deistviia preparata Tserebrolizin pri ishemii arterii golovnogo mozga. Zhurn. nevrologii i psikhiatrii. 2014; 3 (2): 43–50 (in Russian).]
17. Zhang Ch, Chopp M et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010; 88: 3275–81.
18. Ubhi K, Rockenstein E, Vazquez-Roque R et al. Cerebrolysin modulates nerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res 2013; 91: 167–77.
19. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012; 48 (Suppl. A): 3–24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716
20. Boado RJ. Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 1995; 197 (3): 179–82.
21. Boado RJ. Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 1996; 220: 53–6.
22. Boado RJ, Wu D, Pardridge WM, Windisch M. In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain. In: XVI World Congress of Neurology. Buenos Aires, 1997. Abstracts. N. 2–07–06.
23. Boado RJ. Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors. J Neural Transm 1998; 53 (Suppl.): 323–31.
24. Boado RJ. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides. Eur J Neurol 1999; 6 (Suppl. 3): 37.
25. Mooradian AD, Chung HC, Shan GN. GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 1997; 18: 469–74.
26. Windisch M, Piswanger A. In vitro effects of peptide derivates and extracts from calf blood on the oxidative metabolism of brain, liver and heart muscle homogenates of the rat. Drug Res 1985; 35: 87–9.
27. Чуканова Е.И. Сравнительный анализ эффективности Церебролизина при лечении пациентов с хронической ишемией мозга. Фармакоэкономические аспекты. Трудный пациент. 2011; 9 (1): 32–9.
[Chukanova E.I. Sravnitel'nyi analiz effektivnosti Tserebrolizina pri lechenii patsientov s khronicheskoi ishemiei mozga. Farmakoekonomicheskie aspekty. Trudnyi patsient. 2011; 9 (1): 32–9 (in Russian).]
28. Чутко Л.С., Сурушкина С.Ю., Рожкова А.В. и др. Астенические расстройства и когнитивные нарушения у пациентов с головной болью напряжения. Журн. неврологии и психиатрии/ 2013; 5: 25–9.
[Chutko L.S., Surushkina S.Iu., Rozhkova A.V. i dr. Astenicheskie rasstroistva i kognitivnye narusheniia u patsientov s golovnoi bol'iu napriazheniia. Zhurn. nevrologii i psikhiatrii/ 2013; 5: 25–9 (in Russian).]
________________________________________________
2. Poroshina E.G., Nemirovsky V.S. Asthenia, neurasthenia, chronic fatigue syndrome: similarities and differences. Study guide. Ed. prof. V.I.Simanenkova. Saint Petersburg: AST345, 2012 (in Russian).
3. Psikhicheskie rasstroistva i rasstroistva povedeniia (F00–F99). Klass V MKB-10, adaptirovannyi dlia ispol'zovaniia v Rossiiskoi Federatsii. Red. B.A.Kazakovtseva, V.B.Gollanda. Moscow, 1998 (in Russian).
4. Poverennova I.E., Zolotovskaia I.A., Bezginaz E.V. Diagnostika i lechenie astenicheskogo sindroma u lits pozhilogo vozrasta, perenesshikh ORVI. Zhurn. nevrologii i psikhiatrii 2014; 9: 73–6 (in Russian).
5. Shishkova V.N. Neuroprotection in patients with arterial hypertension: minimizing a poor prognosis. Therapeutic Archive. 2014; 86 (8): 113–8 (in Russian).
6. Shishkova V.N. Cognitive impairment as a universal clinical syndrome in the practice of a therapist. Therapeutic Archive. 2014; 86 (11): 128–34 (in Russian).
7. Xiong TY, Redwood S, Prendergast B et al. Coronoviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020: ehaa23. DOI: 10.1093/eurheartj/ehaa231
8. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. DOI: 10.1001/jama.2020.1585
9. The world health report 2002 – Reducing Risks, Promoting Healthy Life. World Health Organization 2002; 186: 192.
10. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017; 11: 372–93.
11. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121 (4): 258–64.
12. Shishkova V.N. Vesennii sezon ostrykh respiratornykh infektsii: chto eto oznachaet dlia komorbidnogo patsienty i kak k nemu podgotovit'sia. Lechebnoe delo. 2019; 4: 122–8 (in Russian).
13. Boldyreva A.A., Stvolinsky S.L., Fedorova T.N. Experimental aspects of cerebral ischemia and oxidative stress. In the book: Essays on angioneurology. Ed. Z.A.Suslina. Moscow: Atmosphere, 2005; p. 41–9 (in Russian).
14. Shishkova V.N. Features of the development of neurological complications in patients with metabolic syndrome: the possibility of correction and prevention. Therapeutic Archive. 2015; 87 (1): 109–14 (in Russian).
15. Shishkova V.N. An elderly comorbid patient: prioritizing. Consilium Medicum. 2019; 21 (9): 48–53. DOI: 10.26442/20751753.2019.9.190500 (in Russian).
16. Gromova O.A., Torshin I.Iu., Gogoleva I.V. Mekhanizmy neirotroficheskogo i neiroprotektornogo deistviia preparata Tserebrolizin pri ishemii arterii golovnogo mozga. Zhurn. nevrologii i psikhiatrii. 2014; 3 (2): 43–50 (in Russian).
17. Zhang Ch, Chopp M et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010; 88: 3275–81.
18. Ubhi K, Rockenstein E, Vazquez-Roque R et al. Cerebrolysin modulates nerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res 2013; 91: 167–77.
19. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012; 48 (Suppl. A): 3–24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716
20. Boado RJ. Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 1995; 197 (3): 179–82.
21. Boado RJ. Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 1996; 220: 53–6.
22. Boado RJ, Wu D, Pardridge WM, Windisch M. In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain. In: XVI World Congress of Neurology. Buenos Aires, 1997. Abstracts. N. 2–07–06.
23. Boado RJ. Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors. J Neural Transm 1998; 53 (Suppl.): 323–31.
24. Boado RJ. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides. Eur J Neurol 1999; 6 (Suppl. 3): 37.
25. Mooradian AD, Chung HC, Shan GN. GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 1997; 18: 469–74.
26. Windisch M, Piswanger A. In vitro effects of peptide derivates and extracts from calf blood on the oxidative metabolism of brain, liver and heart muscle homogenates of the rat. Drug Res 1985; 35: 87–9.
27. Chukanova E.I. Sravnitel'nyi analiz effektivnosti Tserebrolizina pri lechenii patsientov s khronicheskoi ishemiei mozga. Farmakoekonomicheskie aspekty. Trudnyi patsient. 2011; 9 (1): 32–9 (in Russian).
28. Chutko L.S., Surushkina S.Iu., Rozhkova A.V. i dr. Astenicheskie rasstroistva i kognitivnye narusheniia u patsientov s golovnoi bol'iu napriazheniia. Zhurn. nevrologii i psikhiatrii/ 2013; 5: 25–9 (in Russian).
Авторы
В.Н. Шишкова*
ГБУЗ «Центр патологии речи и нейрореабилитации» Департамента здравоохранения г. Москвы, Москва, Россия;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*veronika-1306@mail.ru
Center for Speech Pathology and Neurorehabilitation, Moscow, Russia;
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*veronika-1306@mail.ru
ГБУЗ «Центр патологии речи и нейрореабилитации» Департамента здравоохранения г. Москвы, Москва, Россия;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*veronika-1306@mail.ru
________________________________________________
Center for Speech Pathology and Neurorehabilitation, Moscow, Russia;
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*veronika-1306@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.